Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
John Koreth, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01323920
First received: March 24, 2011
Last updated: February 14, 2014
Last verified: February 2014

March 24, 2011
February 14, 2014
May 2011
February 2013   (final data collection date for primary outcome measure)
Cumulative Incidence of Grade II-IV Acute GVHD by Day 100 After Stem Cell Infusion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To determine the incidence of grade II-IV acute GVHD by day 100 after stem cell infusion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01323920 on ClinicalTrials.gov Archive Site
  • To Assess Percentage Donor Engraftment by Day 30 Post Stem Cell Infusion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To assess percentage donor engraftment by day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) >/= 500 cells/u/L
  • To Assess Non-relapse Mortality, Progression-free and Overall Survival by 1 Year After Stem Cell Infusion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To Determine the Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression by 1 Year After Stem Cell Infusion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To assess percentage donor engraftment by day 30 post stem cell infusion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To assess percentage donor engraftment by day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) >/= 500 cells/u/L
  • To assess non-relapse mortality, progression-free and overall survival by 1 year after stem cell infusion [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To determine the incidence of chronic GVHD requiring systemic immune suppression by 1 year after stem cell infusion [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study

A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. After stem cell transplant, all patients receive prophylactic medications against GVHD.

In this research study, we are studying the safety and effectiveness of a bortezomib based GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call transplantation from a matched unrelated donor, mismatched related or unrelated donor.

Before your transplant you will receive conditioning therapy with fludarabine and busulfan given 7, 6, 5, and 4 days before your transplant. On day 0, you will receive selected blood cells taken from your sibling or unrelated donor.

You will receive 3 drugs for your GVHD prophylaxis:

Tacrolimus will be started 3 days before your transplant. It will be given intravenously and later by mouth. You will continue to take tacrolimus for 3 to 6 months after transplant.

Methotrexate will be given intravenously 1, 3, 6 and 11 days after your transplant.

Bortezomib will be given intravenously 1, 4, and 7 days after your transplant. On days 1, 4, 7, 30 and 3, 6 and 12 months after your transplant you will have a physical exam, blood work, and be asked to complete a questionnaire.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
  • Myelodysplastic Syndrome
Drug: Bortezomib, Tacrolimus, Methotrexate
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV
Other Name: Velcade
Experimental: Velcade/Tac/MTX

Drug: Bortezomib, Tacrolimus, Methotrexate

Other Names:

Velcade Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV

Intervention: Drug: Bortezomib, Tacrolimus, Methotrexate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
November 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced and/or aggressive hematologic malignancy (including myelodysplastic syndrome) that is unlikely to be cured by alternative therapies
  • HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor
  • ECOG performance status 0-2
  • Adequate organ function
  • Able to understand and willing to sign a written informed consent document
  • Agrees to practice adequate contraception per study requirements

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Recipient of prior allogeneic or autologous stem cell transplantation
  • Prior abdominal radiation therapy
  • HIV-positive on combination antiretroviral therapy
  • Seropositive for hepatitis B or C
  • Allergies to bortezomib, boron, or mannitol
  • Myocardial infarction within last 6 months, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias
  • Uncontrolled bacterial, viral or fungal infections
  • Seizures or history of seizures
  • History of another non-hematologic malignancy unless disease-free for at least 5 years
  • Uncontrolled intercurrent illness
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01323920
11-007
Yes
John Koreth, MD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Not Provided
Principal Investigator: John Koreth, MBBS, DPhil Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP